You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Type 2 Inflammation

ADVENT Forum 2022 | Multidisciplinary Management of Patients with Type 2 Inflammatory Diseases

Prof. Arjan Bredenoord and Drs. Bob Geng, Lawrence Eichenfield, Michael Wechsler, and Michael Blaiss review patient burden associated with type 2 inflammatory diseases and the need for multidisciplinary management

Bob Geng
Lawrence F. Eichenfield
Michael Wechsler
MD
Bob Geng +4 more

Learning objectives

  • Describe the evolution of type 2 inflammation from protection to pathology
  • Examine the shared and distinct roles of type 2 inflammatory mediators in the pathology of diseases with underlying type 2 inflammation
  • Highlight the importance of a multidisciplinary approach and shared decision-making in the patient-centered care in type 2 inflammatory diseases
  • Evaluate the latest clinical data for biologics in atopic dermatitis and in asthma in pediatric patients

Description

Arjan Bredenoord, MD, PhD; Bob Geng, MD; Lawrence Eichenfield, MD; Michael Wechsler, MD; and Michael Blaiss, MD, review patient burden associated with type 2 inflammatory diseases and the need for multidisciplinary management and shared-decision making  to improve outcomes and overall patient experience.

Tags
multidisciplinary caresymptomsquality of life
MAT-GLB-2205551 v2.0 01/2023

About these experts

Allergy/Immunology
MD

Bob Geng

Co-Director of the Multidisciplinary Atopic Dermatitis Program | Rady Children's Hospital, San Diego | Associate Clinical Professor | UC San Diego School of Medicine, California, United States

Dermatology
MD

Lawrence F. Eichenfield

Vice Chair of the Department of Dermatology | University of California San Diego (UCSD) School of Medicine; Chief of Pediatric and Adolescent Dermatology | Rady Children’s Hospital San Diego, California, United States

Pulmonology
MD, MMSc

Michael Wechsler

Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine | National Jewish Health, Colorado, United States

Allergy/Immunology
FAAAAI, FACAAI, MD

Michael Blaiss

Clinical Professor of Pediatrics | Medical College of Georgia; Allergist | Good Samaritan Health Center of Gwinnett, Georgia, United States

Gastroenterology
MD, PhD

Arjan Bredenoord

Professor of Neurogastroenterology & Motility | University of Amsterdam, Netherlands; Consultant Gastroenterologist | Amsterdam University Medical Centers

Related resources

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions
Dermatology
Infographic

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions

Expert Case Series: Determining Treatment in a Pediatric Patient With Severe AD
Dermatology
interactivity

Expert Case Series: Determining Treatment in a Pediatric Patient With Severe AD

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics
Dermatology
interactivity

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics

Prurigo Nodularis (PN) Case Studies
Dermatology
interactivity

Prurigo Nodularis (PN) Case Studies

The Role of Type 2 Inflammation in Multiple Disease Trajectories
Type 2 Inflammation
interactivity

The Role of Type 2 Inflammation in Multiple Disease Trajectories

Type 2 Inflammation and Neuronal Sensitization in AD and PN
Dermatology
interactivity

Type 2 Inflammation and Neuronal Sensitization in AD and PN

Recognizing the Complex, Multi-Dimensional Impact of AD on Adult Patients
Dermatology
Infographic

Recognizing the Complex, Multi-Dimensional Impact of AD on Adult Patients

Tools For a Holistic Assessment of Atopic Dermatitis Across Age Groups
Dermatology
slide presentation

Tools For a Holistic Assessment of Atopic Dermatitis Across Age Groups

Type 2 Inflammation, Neurosensitization, and Chronic Itch in Atopic Dermatitis
Dermatology
interactivity

Type 2 Inflammation, Neurosensitization, and Chronic Itch in Atopic Dermatitis

Skin Barrier Dysfunction and the Increased Risk For Allergen Sensitization in Children With Atopic Dermatitis
Dermatology
Infographic

Skin Barrier Dysfunction and the Increased Risk For Allergen Sensitization in Children With Atopic Dermatitis

Effect of Type 2 Inflammation on Skin Barrier Function in AD​
Dermatology
interactivity

Effect of Type 2 Inflammation on Skin Barrier Function in AD​

Eosinophilic Esophagitis (EoE) Interactive Patient Case
Gastroenterology
interactivity

Eosinophilic Esophagitis (EoE) Interactive Patient Case

Type 2 Inflammation in CRSwNP: Interactive Patient Case
Rhinology
interactivity

Type 2 Inflammation in CRSwNP: Interactive Patient Case

Partnering With Patients: Scores That Matter in CRSwNP
Rhinology
interactivity

Partnering With Patients: Scores That Matter in CRSwNP

Pediatric Asthma Patient Case Tool: Ash
Pulmonology
interactivity

Pediatric Asthma Patient Case Tool: Ash

Adult Asthma Interactive Patient Cases
Pulmonology
interactivity

Adult Asthma Interactive Patient Cases

The Pathophysiology of Type 2 Inflammation in CRSwNP
Rhinology
interactivity

The Pathophysiology of Type 2 Inflammation in CRSwNP

Chronic Spontaneous Urticaria (CSU) Interactive Patient Case
Dermatology
interactivity

Chronic Spontaneous Urticaria (CSU) Interactive Patient Case

EoE: A Chronic, Progressive, Type 2 Inflammatory Disease
Gastroenterology
Infographic

EoE: A Chronic, Progressive, Type 2 Inflammatory Disease

Pediatric EoE Disease Burden Infographic
Gastroenterology
Infographic

Pediatric EoE Disease Burden Infographic

ADVENT On Air | Defining AD in Pediatric Patients
Dermatology
audio

ADVENT On Air | Defining AD in Pediatric Patients

Explore the Global Burden of Atopic Dermatits in Children and Adolescents
Dermatology
interactivity

Explore the Global Burden of Atopic Dermatits in Children and Adolescents

GINA Guidelines For Improved Outcomes With Effective Management of Pediatric Asthma
Pulmonology
interactivity

GINA Guidelines For Improved Outcomes With Effective Management of Pediatric Asthma

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)
Dermatology
Infographic

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management
Dermatology
Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU
Dermatology
Infographic

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients
Rhinology
interactivity

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

ADVENT On Air | Loss of Smell in CRSwNP Patients
Rhinology
audio

ADVENT On Air | Loss of Smell in CRSwNP Patients

The Role of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU)
Dermatology
Infographic

The Role of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU)

The Role of Mast Cells, Basophils and Type 2 Cells and Cytokines in CSU
Dermatology
interactivity

The Role of Mast Cells, Basophils and Type 2 Cells and Cytokines in CSU

Chronic Spontaneous Urticaria: Disease Overview
Dermatology
interactivity

Chronic Spontaneous Urticaria: Disease Overview

Diagnostic Algorithm for Patients Presenting with Wheals and/or Angioedema
Dermatology
interactivity

Diagnostic Algorithm for Patients Presenting with Wheals and/or Angioedema

OCS Use in Asthma is Associated with Adverse Events Infographic
Infographic

OCS Use in Asthma is Associated with Adverse Events Infographic

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?
Dermatology
interactivity

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?

The Common Dysfunction Across Different Dermatologic Diseases: Type 2 Inflammation, the Neuroimmune Axis, and Skin Tissue Interactions in AD and PN
Dermatology
Infographic

The Common Dysfunction Across Different Dermatologic Diseases: Type 2 Inflammation, the Neuroimmune Axis, and Skin Tissue Interactions in AD and PN

ADVENT On Air | Remission in CRSwNP
Rhinology
audio

ADVENT On Air | Remission in CRSwNP

Tools for Clinical Assessment of Prurigo Nodularis
Dermatology
Infographic

Tools for Clinical Assessment of Prurigo Nodularis

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients
Pulmonology
Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

Skin Dyspigmentation In Prurigo Nodularis (PN)
Dermatology
interactivity

Skin Dyspigmentation In Prurigo Nodularis (PN)

Expert Case Series: The Burden of AD in Pediatric Patients
Dermatology
interactivity

Expert Case Series: The Burden of AD in Pediatric Patients

Children and EoE: More Than Just Being a Picky Eater
Gastroenterology
expert video

Children and EoE: More Than Just Being a Picky Eater

EoE Burden and Pathophysiology of Type 2 Inflammation
Gastroenterology
videoanimation

EoE Burden and Pathophysiology of Type 2 Inflammation

Food Bolus Impaction: An Opportunity to Diagnose EoE
Gastroenterology
expert video

Food Bolus Impaction: An Opportunity to Diagnose EoE

Gap in Care Leads to Progression of Fibrosis in EoE
Gastroenterology
expert video

Gap in Care Leads to Progression of Fibrosis in EoE

Impact of Delayed EoE Diagnosis on Disease Progression and QoL
Gastroenterology
expert video

Impact of Delayed EoE Diagnosis on Disease Progression and QoL

Managing the Risk of Fibrostenosis in EoE
Gastroenterology
expert video

Managing the Risk of Fibrostenosis in EoE

The Need for Maintenance Therapy in EoE
Gastroenterology
expert video

The Need for Maintenance Therapy in EoE

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region